H. Kim et al., High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma, J PHARM B, 24(3), 2001, pp. 461-468
Temozolomide (SCH 52365; TEMODAL(TM)) is an antineoplastic agent with activ
ity against a broad spectrum of murine tumors. This compound is currently m
arketed in the European Union for the treatment of patients with glioblasto
ma multiforme and anaplastic astrocytoma, which are serious and aggressive
types of brain cancers. It has been postulated that temozolomide exerts its
in vivo activity via the decomposition product MTIC, which is believed to
alkylate nucleophiles, and in the process is converted to AIC. A high-perfo
rmance liquid chromatographic (HPLC) method was developed and validated for
the analysis of temozolomide in human plasma. The determination of temozol
omide involved extraction with ethyl acetate followed by separation on a re
versed phase C-18 column and quantification by UV absorbance at 316 nm. The
calibration curve was linear over a concentration range of 0.1-20 mug/ml.
The limit of quantitation was 0.1 mug/ml, where the coefficient of variatio
n (CV) was 0% and the bias was 10.0%. The method was precise with a coeffic
ient of Variation ranging from 2.5 to 6.9% and accurate with a bias ranging
from - 5.0 to 10.0%. Temozolomide was unstable at 37 degreesC in human pla
sma with a degradation t(1/2) of 15 min; however, it was stable at 4 degree
sC for at least 30 min. Temozolomide was stable in acidified human plasma (
pH < 4) for at least 24 h at 25<degrees>C, and for at least 30 days at - 20
degreesC. Moreover, temozolomide was stable in acidified human plasma afte
r being subjected to three freeze-thaw cycles. The assay was shown to be sp
ecific, accurate, precise, and reliable for use in pharmacokinetic studies.
(C) 2001 Elsevier Science B.V. All rights reserved.